Ask AI
ProCE Banner Activity

CELMoDs in Multiple Myeloma

Clinical Thought

In this commentary derived from a recent symposium, experts discuss CELMoD therapy for multiple myeloma, including the mechanism of action, available clinical data, ongoing trials, and future implications.

Released: July 28, 2025

Expiration: January 27, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Jesus Berdeja, MD: consultant: AstraZeneca, Bristol Myers Squibb, Galapagos, Genentech, Johnson & Johnson, Karyopharma, Kite, Kyowa Kirin, Pfizer, Regeneron, Roche, Sebia; researcher: 2 Seventy Bio, AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, Genentech, GSK, Gracell, Ichnos Sciences, Johnson & Johnson, Juno Therapeutics, K36 Therapeutics, Karyopharm, Kite, Moderna, Pfizer, Regeneron, Roche, Sanofi, Takeda; speaker: Janssen.

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Sanofi; individual publicly traded stocks and stock options: Arcellx, Bristol Myers Squibb.

Sagar Lonial, MD, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; other financial or material support: TG Therapeutics.